Table 1

Demographic and disease characteristics

(n = 599)


Agea (years)

56.81 (10.84)

Disease durationb (years)

12 (20-6)

Sex,a F (%)

457 (76.29)

CRP at baseline, median (IQR) mg/Lb

34 (17-63)

ESR at baseline, median (IQR) mg/Lb

43 (27-68)

DAS28 at baselinea

6.36 (0.90)

Change in DAS28a

-2.01 (1.23)

Concurrent DMARD n (%)

449 (74.96)

Infliximab

272 (45.41)

Etanercept

220 (36.73)

Adalimumab

107 (17.86)


CRP, C-reactive protein; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; F, female; IQR, interquartile range; SD, standard deviation. aValues are expressed as mean (SD). bValues are expressed as median (IQR). All other values are n (%). Disease duration was measured in 598 patients; erythrocyte sedimentation rate (ESR) levels were measured in 578 patients; and change in DAS28 was measured in 442 patients.

Plant et al. Arthritis Research & Therapy 2012 14:R214   doi:10.1186/ar4052

Open Data